A legacy of innovation and performance
Founded in 2010 in New York City, Aquavit was born with a clear vision: to modernise and personalise healthcare through advanced technologies.
With over 30 patents and 25 registered trademarks, Aquavit establishes itself as a global leader in micro-administration technologies and intradermal applications.
This expertise has given rise to the iconic AQUAGOLD® Finetouch™, a revolutionary cosmetic tool.
The Story of AQUAGOLD®
Founded in 2010 in New York City, Aquavit was built on a clear vision: to redefine skincare through innovation and precision. From the very beginning, a scientific council was established, leading to the filing of the first patent (PITO-001) and the development of the core technologies behind AQUAGOLD®.
In 2014, AQUAGOLD® fine touch™ was introduced to the medical world at the American Academy of Dermatology, marking the beginning of its clinical adoption. By 2015, the first patent was officially secured in South Korea, strengthening its technological foundation.
Between 2016 and 2018, AQUAGOLD® experienced rapid growth and international recognition. The device achieved FDA compliance, while patents were granted in the United States and Europe. During this period, new innovations such as iMicrotox™ were developed, alongside the acquisition of a GMP-certified manufacturing facility.
From 2019 onward, Aquavit expanded its vision beyond aesthetics, exploring new applications including vaccine delivery technologies and developing advanced injectable formulations. In 2023, the brand introduced an intelligent skin analysis platform, further integrating technology into personalized skincare.
Today, AQUAGOLD® continues its expansion in Europe, bringing its expertise to a new generation of practitioners. As an official distributor, AQUAGOLD® Europe is committed to delivering high-quality, innovative solutions, supporting professionals with reliable tools, and redefining aesthetic treatments through precision and performance.
Join the evolution of AQUAGOLD® and discover a new standard in advanced skincare.
THE KEY STAGES OF AQUAVIT AND AQUAGOLD®
Founded in 2010 in New York City, Aquavit was born with a clear vision: to modernise and personalise healthcare through advanced technologies.
With over 30 patents and 25 registered trademarks, Aquavit establishes itself as a global leader in micro-administration technologies and intradermal applications.
This expertise has given rise to the iconic AQUAGOLD® Finetouch™, a revolutionary cosmetic tool.
The beginnings of a visionary innovation
2010: Foundation of Aquavit in New York City
2011: Establishment of a Scientific Council and filing of the first patent (PITO-001)
2013: Development of fundamental technologies for AQUAGOLD®
Launch of AQUAGOLD® Finetouch™
2014: Pilot launch at the American Academy of Dermatology. Collaboration with Korean partners for production.
2015: Obtaining the PITO-001 patent in South Korea.
Expansion and international recognition
2016: FDA Compliance for the AQUAGOLD® AQT series.
2017: Patents obtained in the United States and Europe.
2018: Development of innovations such as iMicrotox™ and acquisition of a GMP-compliant factory.
Diversification and new horizons
2020: Innovations for the delivery of vaccines (HPV, COVID-19).
2021: Development of new patented injectable compositions.
2023: Launch of an intelligent skin analysis platform.
2025: AQUAGOLD® in Europe
With a rich history and constant innovations, AQUAGOLD® is establishing itself in Europe to offer professionals cutting-edge cosmetic tools.
As an official distributor, AQUAGOLD® Europe is committed to:
Provide high-quality solutions tailored to the standards and needs of the European market.
Support professionals in their practice with reliable products and dedicated resources.
Redefining aesthetic care through a technology that combines innovation and effectiveness.
Join the story of AQUAGOLD® and discover how our expertise can transform your aesthetic treatments.